Skip to main content
. Author manuscript; available in PMC: 2024 Jul 23.
Published in final edited form as: FASEB J. 2023 Mar;37(3):e22825. doi: 10.1096/fj.202201972RR

FIGURE 5.

FIGURE 5

eNAMPT-neutralizing ALT-100 mAb reduces plasma cytokine levels and biochemical indices of hepatic fibrosis in STZ/HFD mice. (A) Plasma ALT levels were elevated in STZ/HFD compared to normal mice with levels similar in vehicle-treated NASH mice compared to ALT-100 mAb NASH mice. (B) Elevated plasma eNAMPT levels in STZ-HFD mice were significantly reduced in ALT-100 mAb-treated mice (*p < .05 vs. Ctrl, vs. Veh/STZ-HFD, respectively). (C) Plasma levels of IL-6 in STZ-HFD mice were similar in mice receiving the ALT-100 mAb. (D) Increased plasma levels of TNFα in STZ-HFD mice were significantly reduced in mice receiving the ALT-100 mAb (*p < .05 vs. Veh/STZ-HFD). (E–G) Quantitation of NAMPT immunoblot intensity in hepatic lysates from STZ-HFD mice showed that treatment with ALT-100 resulted in significantly decreased expression of NAMPT and SNAi1 (*p < .05 vs. Veh/STZ-HFD).